Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone (Q84530206)
Jump to navigation
Jump to search
scientific article published on 03 June 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone |
scientific article published on 03 June 2010 |
Statements
Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone (English)
Franck E Nicolini
Sandrine Hayette
Laurence Legros
Philippe Rousselot
Frédéric Maloisel
Michel Tulliez
Agnès Guerci
Aude Charbonnier
Françoise Rigal-Huguet
Kaddour Chabane
Jean-Pierre Magaud
Carole Paillet
Christine Pivot
Mauricette Michallet